NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...
Q4 2024 Earnings Call Transcript March 3, 2025 Fortrea Holdings Inc. misses on earnings expectations. Reported EPS is $0.18 ...
The responses escalated the trade war that has rattled governments and international relations. The Trump administration’s ...
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
AbbVie (NYSE: ABBV) and Gubra A/S (CPSE:GUBRA), a company specializing in preclinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, today ...
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent ...
7h
The operating room equipment market is experiencing strong growth, driven by the increasing volume of surgical procedures across specialties such as ...
Teck Resources will try to sell zinc to Asia instead of the U.S. to contend with new tariffs imposed by the Trump ...
A live audio webcast of the Company’s fireside chat at the Barclays Global Healthcare Conference can be accessed here or by visiting Events & Presentations in the Investor Relations section on the ...
FORWARD-53 is an ongoing Phase 2 open-label trial of WVE-N531. Muscle biopsies are taken after 24 and 48 weeks of dosing. The ...
Q4 2024 Earnings Conference Call March 3, 2025 6:00 PM ET. Company Participants. Scott Kozak – Director of Investor Relations John Hopkins ...
10h
Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback